Biosimilars have become increasingly popular in the last few years.
Recently, there’s been an uptick in studies and articles about functional dyspepsia (FD). The reason is probably that FD is quite common (10% to 15% of the US population has it), and many clinicians fail to differentiate FD from other gastrointestinal disturbances.
Pharmacists who launched marketing campaigns for flu shots in late summer may have jumped the gun for their older patients.
The FDA recently approved Aralez Pharmaceuticals’ Yosprala, a once-daily, fixed-dose combination of the antiplatelet agent aspirin and the proton pump inhibitor omeprazole.